Quotables
"Everyone acquainted with the subject will recognize it as a conspicuous failure."
Henry Morton, president of the Stevens Institute of Technology ; Said in 1880 about the light bulb
PatentStorm News
Make the Most of Our Site
See this month's Top Inventors and Most Cited Patents.
Stay on top of the latest innovations by subscribing to an RSS feed.
Registered users: Manage your profile.
| Number | Title | Issue Date |
| 7659117 | Compositions and methods for dendritic cell-based immunotherapy Disclosed are immunostimulatory fusion proteins and methods for generating protective DC-induced, T cell-mediated immune responses in vitro and in vivo. The immunostimulatory fusion proteins comprise a polypeptide antigen component and an immunostimulatory component... | 02/09/2010 |
| 7442547 | Dendritic cells and the uses thereof in screening cellular targets and potential drugs The present invention is based on the discovery that in response to different stimuli, dendritic cells initiate various immune responses by producing different transcription profiles, e.g., IL-2 production by dendritic cells in response to a microbial stimulus. The ... | 10/28/2008 |
| 7371921 | Nonhuman animal model non-responsive to mycoplasma-origin lipoprotein/lipopeptide An object of the present invention is to provide a non-human animal model unresponsive to a mycoplasma-derived lipoprotein/lipopeptide, and a method for screening an inhibitor or a promoter for a response to a mycoplasma-derived lipoprotein with the use of the non-h... | 05/13/2008 |
| 7368287 | Use of L-α-lysophosphatidylcholine to obtain the differentiation of monocytes into mature dendritic cells in vitro The present invention relates to the use of L-α-lysophosphatidylcholine and/or an equivalent compound for the differentiation of monocytes into mature denditric cell. The present invention also relates to a method for differentiation monocytes into mature de... | 05/06/2008 |
| 7364900 | Multi-lineage directed induction of bone marrow stromal cell differentiation Methods of inducing differentiation of mammalian bone marrow stromal cells into cells of multiple embryonic lineages by contacting marrow stromal cells with precursor differentiation-inducing compounds followed by contacting the partially differentiated precursor ce... | 04/29/2008 |
| 7358087 | Compositions and methods for enhancing immune responses mediated by antigen-presenting cells Molecular adjuvants are disclosed comprising an antigen presenting cell-targeting ligand linked to an immunogen. In particular, these molecular adjuvants are employed in compositions designed to deliver the specific immunogen to antigen presenting cells and simultan... | 04/15/2008 |
| 7288250 | Monoclonal antibodies against HMGB1 In various embodiments, the present invention is drawn to antibodies or antigen-binding fragments thereof that bind to a vertebrate high mobility group box (HMGB) polypeptide, methods of detecting and/or identifying an agent that binds to an HMGB polypeptide, method... | 10/30/2007 |
| 7273753 | Purification and uses of dendritic cells and monocytes Methods for the preparation of substantially purified populations of dendritic cells and monocytes from the peripheral blood of a mammal is described. Also described are vaccine compositions and methods for the treatment of certain diseases and medical conditions ba... | 09/25/2007 |
| 7252996 | Ancillary composition for the preparation of committed mature dentritic cells The invention consists in the use of a maturation agent comprising a mixture of ribosomal and/or membrane fractions for the preparation of mature dendritic cells from immature dendritic cells. ... | 08/07/2007 |
| 7238360 | Alteration of cell membrane with B7 Methods and compositions are provided for the persistent modification of cell membranes with exogenous proteins so as to alter the function of the cell to achieve effects similar to those of gene therapy, without the introduction of exogenous DNA. DNA sequences, the... | 07/03/2007 |
| 7160723 | Cell separation compositions and methods The invention provides compositions and methods for cell separation. These reagents and techniques specifically agglutinate cells via surface antigen recognition and can be used to recover even rare cell types in high yield. ... | 01/09/2007 |
| 7070996 | Production of cultured human mast cells and basophils for high throughput small molecule drug discovery Provided are methods for producing and screening proliferated populations of CD34-negative progenitor cells, mucosal mast cells, connective tissue-type mast cells and basophil cells. The methods generate uniform proliferated populations of cells. The proliferated po... | 07/04/2006 |
| 7063851 | Herpes viruses for immune modulation A method of stimulating an immune response in a human or animal subject, which method comprises administering to a subject in need thereof an effective amount of an attenuated herpes virus which: (i) lacks a functional vhs gene, or... | 06/20/2006 |
| 7033784 | Method of producing an erythroid cell which is undifferentiated yet capable of expressing a heterologous protein A method of producing an erythroid cell which is substantially undifferentiated but which is capable of expressing a heterologous protein under the control of a globin promoter thereof, which method comprises maintaining growing uninduced erythroid cells in culture ... | 04/25/2006 |
| 7033806 | HY2 family of bilin reductases This invention identifies a novel family of bilin reductases. Designated herein HY bilin reductases, the enzymes of this invention are useful in a wide variety of contexts including but not limited to the conversion of biliverdins to phytobilins and the assembly of ... | 04/25/2006 |
| 6982082 | Gene therapy by cell specific targeting This invention is directed to a modified cyclosporin A and to a modified, genetically engineered version of its receptor, cyclophilin. This invention is further directed to a method for treating host versus graft disease following blood marrow transplantation by tra... | 01/03/2006 |
| 6953874 | Transgenic animals having a modified glycoprotein V gene The present invention relates to nonhuman transgenic animals in which the GP V gene has been modified. The invention is also useful for identifying agents that modulate the biological functions of GP V, including the screening and identification of potential therape... | 10/11/2005 |
| 6946260 | Allergen/inflammatory testing and diagnosis The invention relates to the use of a secretor variant cell-line expressing the alpha moiety of human IgE binding protein to determine the allergic status of a given individual. Moreover, the cell-line is also used to provide an assay system for determining the alle... | 09/20/2005 |
| 6933148 | Cell separation compositions and methods The invention provides compositions and methods for cell separation. These reagents and techniques specifically agglutinate cells via surface antigen recognition and can be used to recover even rare cell types in high yield. ... | 08/23/2005 |
| 6908763 | Mammalian common lymphoid progenitor cell A substantially enriched mammalian hematopoietic cell subpopulation is provided, which is characterized by progenitor cell activity for lymphoid lineages, but lacking the potential to differentiate into myeloid and erythroid lineages. Methods are provided for the is... | 06/21/2005 |
| 6852537 | Transgenic circulating endothelial cells A process is provided for expanding the population of endothelial cells obtained from peripheral blood which can be transformed with a vector comprising a DNA sequence encoding a preselected bioactive polypeptide. The resulting transgenic endothelial cells are usefu... | 02/08/2005 |
| 6852533 | Purified populations of stem cells The invention is directed to a purified population of mammalian endothelial, muscle, or neural stem cells. The invention further provides methods for isolating such populations of cells; methods for using such populations of cells for treating mammals; methods for m... | 02/08/2005 |
| 6852515 | Stimulation of angiogenesis via enhanced endothelial expression of syndecan-4 core The present invention provides tangible means and methods for stimulation of angiogenesis via enhanced endothelial expression of core proteins having a syndecan-4 cytoplasmic region intracellularly. The tangible means include a prepared DNA sequence fragment having ... | 02/08/2005 |
| 6838081 | Methods for enhancing antigen-presenting cells and anti-tumor responses in a human patient The present invention provides methods for enhancing the development of APC from precursor cells by administering a combination of GM-CSF and IL-4. The precursor cells include: cells contained in peripheral blood, CD14+ cells and precursors in bone... | 01/04/2005 |
| 6835566 | Human lineage committed cell composition with enhanced proliferative potential, biological effector function, or both; methods for obtaining same; and their uses A method for obtaining lineage committed human cells imbued with enhanced proliferative potential, biological function, or both, comprising culturing lineage committed human cells under physiologically acceptable liquid culture conditions, where the liquid culture m... | 12/28/2004 |
| 6812023 | Methods of producing membrane vesicles The present invention relates to methods of preparing biological material, for use in various experimental, diagnostic or therapeutic uses, including immunotherapy treatment or prophylaxy of tumors. More particularly, the present invention relates to methods of prep... | 11/02/2004 |
| 6784155 | Inhibitor and stimulator of stem cell proliferation and uses thereof Disclosed and claimed are methods for the isolation and use of stem cell modulating factors for regulating stem cell cycle and for accelerating the post-chemotherapy peripheral blood cell recovery. Also disclosed and claimed are the inhibitors and stimulators of ste... | 08/31/2004 |
| 6750028 | Anti-fibrotic agent assay A novel method has been developed for screening anti-scarring and anti-fibrotic agents. This method offers simplicity, it is reproducible and could be adopted to screen large numbers of new potential ant-fibrotic agents. This method has characteristics in common wit... | 06/15/2004 |
| 6676937 | Compositions and methods for modulating vascularization The present invention generally provides methods for modulating formation of new blood vessels. In one embodiment, the methods include administering to a mammal an effective amount of granulocyte macrophage-colony stimulating factor (GM-CSF) sufficient to... | 01/13/2004 |
| 6649595 | Regulation of biological events using novel compounds Materials and methods are disclosed for regulation of biological events such as target gene transcription and growth, proliferation or differentiation of engineered cells.... | 11/18/2003 |
| 6627426 | Methods for reducing adventitious agents and toxins and cell culture reagents produced thereby The present invention relates generally to a method to reduce, substantially reduce, inactivate or eliminate adventitious agents and/or toxins in a sample, particuarly in nutritive media, media supplements, media subgroups and buffer formulations. Specifi... | 09/30/2003 |
| 6583333 | Lymphoma-susceptible transgenic mice and methods for studying drug sensitivity of lymphomas A mouse expressing myc in B cells, because of defective function of one or more tumor suppressor genes, is useful for the testing of anti-lymphoma agents and for the testing of genes which may have an effect on the apoptotic pathway. Preferred embodiments... | 06/24/2003 |
| 6548299 | Lymphoid tissue-specific cell production from hematopoietic progenitor cells in three-dimensional devices The invention relates to a method for lymphoid tissue-specific cell production from hematopoietic progenitor cells in unique, three-dimensional culture devices, in the presence of lymphoreticular stromal cells and in the absence of exogenously added growt... | 04/15/2003 |
| 6540994 | Macrophages, process for preparing the same and their use as active substances of pharmaceutical compositions The invention relates to macrophages which have at least one of the following properties: their cytotoxic activity without IFN-7 is increased by about 20 to 30% with respect to standard macrophages, and is preferably of about 70%; their cytotoxic activity... | 04/01/2003 |
| 6524815 | VE-cadherin promoter and its uses The invention relates to the isolation and cloning of the VE-cadherin promoter. It also relates to transformed cells and transgenic animals containing the VE-cadherin promoter. The VE-cadherin promoter of the invention is particularly useful for the tissu... | 02/25/2003 |
| 6524855 | Methods for inducing the differentiation of monocytes into functional dendritic cells A method for inducing differentiation of monocytes contained in an extracorporeal quantity of a subject's blood into functional dendritic antigen presenting cells is provided. The monocytes are first treated by exposure to physical perturbation, irradiati... | 02/25/2003 |
| 6498034 | Method of producing dendritic cells The present invention relates to a method for producing dendritic cells from human hematopoietic progenitor cells by obtaining a cell sample that includes human progenitor cells and culturing the cell sample under plasma-free and serum-free conditions in ... | 12/24/2002 |
| 6482926 | Antibody compositions for preparing enriched cell preparations The present invention relates to antibody composition that are useful in preparing enriched cell preparations such as human hematopoietic progenitor cells and stem cells and non-hematopoietic tumor cells. The invention also relates to kits for carrying ou... | 11/19/2002 |
| 6465247 | Mammalian myeloid progenitor cell subsets A substantially enriched mammalian hematopoietic cell subpopulation is provided, which is characterized by progenitor cell activity for myeloid lineages, but lacking the potential to differentiate into lymphoid lineages. This population is further divided... | 10/15/2002 |
| 6465251 | Method of promoting b-cell proliferation and activation with CD40 ligand and cyclosporin We teach a strategy to obtain large quantities of desired APCs, activated B cells, which are superior in their capacity to present tumor protein antigen in a multiadministration protocol. Human B cells can be obtained from peripheral blood in large number... | 10/15/2002 |
